Shandong Buchang Pharmaceuticals Co (SHSE:603858) LT-Debt-to-Total-Asset : 0.12 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Shandong Buchang Pharmaceuticals Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Shandong Buchang Pharmaceuticals Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.12.

Shandong Buchang Pharmaceuticals Co's long-term debt to total assets ratio increased from Mar. 2023 (0.09) to Mar. 2024 (0.12). It may suggest that Shandong Buchang Pharmaceuticals Co is progressively becoming more dependent on debt to grow their business.

Shandong Buchang Pharmaceuticals Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Shandong Buchang Pharmaceuticals Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Buchang Pharmaceuticals Co LT-Debt-to-Total-Asset Chart

Shandong Buchang Pharmaceuticals Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

0.08

0.10

Shandong Buchang Pharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.09	0.10	0.11	0.10	0.12

Shandong Buchang Pharmaceuticals Co LT-Debt-to-Total-Asset Calculation

Shandong Buchang Pharmaceuticals Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	2109.37	/	20892.298
	=	0.10

Shandong Buchang Pharmaceuticals Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	2556.679	/	21306.417
	=	0.12

Shandong Buchang Pharmaceuticals Co (SHSE:603858) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Shandong Buchang Pharmaceuticals Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Shandong Buchang Pharmaceuticals Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Shandong Buchang Pharmaceuticals Co (SHSE:603858) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Buchang Pharmaceuticals Co Ltd (SHSE:603858) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

No. 369, Zhonghua West Road, Shandong Province, Heze, CHN, 274000

Website

http://www.buchang.com

Shandong Buchang Pharmaceuticals Co Ltd is a pharmaceuticals company engaged in drug manufacturing. It specializes in the research and development, production and sale of Traditional Chinese patent medicines, supplemented by fields such as hi-tech industry and health industry. The company offers drugs for cardiac and cerebral vascular disease, diabetes, urinary and digestive disease, respiratory disease, gynecological disease and others. Geographically, the company holds its production bases in Shandong, Shaanxi, Hebei and Northeast China, with its marketing network spreading all over the major provinces of China.

Shandong Buchang Pharmaceuticals Co (SHSE:603858) Headlines

No Headlines